Reversible Posterior Leukoencephalopathy Syndrome
ICD-10 I67.8; I67.4 · ICD-11 8B22.Y.1

RPLS with Acute Hypertension: What to Do When First-Line Antihypertensive Agents Have Not Achieved Blood Pressure Targets

In reversible posterior leukoencephalopathy syndrome with acute hypertension, management begins with first-line continuous intravenous antihypertensive agents alongside supportive measures. When that initial step fails to bring blood pressure within the required range, a defined escalation protocol takes over.

Previous Line: First-Line Agents Insufficient

Initial therapy with first-line continuous intravenous antihypertensive agents — including labetalol, nicardipine, or nimodipine — did not achieve the required blood pressure targets: a gradual reduction of no more than 20–25% within the first few hours, with a mean arterial pressure between 105 and 125 mm Hg.

Clinical Targets

The blood pressure goals remain unchanged for this escalation step: reduce blood pressure gradually by no more than 20–25% in the first few hours, aiming for a mean arterial pressure of 105–125 mm Hg. Continuous intravenous administration is typically required to sustain this control.

Escalation Approach (Partial Overview)

This protocol escalates to second-line intravenous antihypertensive agents. Agent selection, specific dosing guidance, sequencing, and monitoring parameters are detailed in the full structured regimen below.

References

DOI: 10.1136/practneurol-2021-003194
First-line antihypertensive agents include nicardipine (5–15 mg/hour), labetalol (2–3 mg/min) and nimodipine; second-line agents include sodium nitroprusside, hydralazine and diazoxide.
Patients with acute hypertension should have their blood pressure gradually reduced by no more than 20%–25% in the first few hours to avoid the risk of cerebral, coronary and renal ischaemia.
Clinicians should aim for a mean arterial pressure of between 105 and 125 mm Hg, and continuous intravenous infusions are often required.
View source ↗